When a Price Cap Nearly Cost Cancer Patients Their Only Chemotherapy Drug

A Price Meant to Protect Patients Nearly Cut Off Their Only Chemotherapy Option A 50

percent price hike on a cancer drug sounds, on its face, like bad news for patients. Here it was the opposite - it was the intervention that kept the drug on the shelf at all. That inversion is the actual story behind India's cisplatin and carboplatin shortage and it says more about how price control works in practice than any aggregate healthcare statistic could.

Start with the number that actually moved: the global price of platinum, the core raw material in both drugs, more than doubled over the past year, compounded by shipping disruptions through West Asia that squeezed the flow of imported active pharmaceutical ingredients.

NPPA's ceiling price for cisplatin, however, had stayed fixed at ₹7.26 per mL - a rate set for a world where platinum cost a fraction of what it does now. For a generic manufacturer, that gap between rising input cost and a frozen selling price is not a margin problem, it is a shutdown decision.

Several manufacturers simply stopped the production line. The people who felt this first were not abstract "patients" but a specific, split population. In government-run centres - Kerala's Regional Cancer Centre, Delhi State Cancer Institute, Bengaluru's Kidwai Memorial Institute - multi-vendor tenders and central procurement through the Central Medical Store meant stock lasted long enough to absorb the shock.

In Hyderabad's Mehdi Nawaz Jung Institute, by contrast, monthly demand ran into the thousands of vials while procurement delivered only a few hundred - a state-run hospital serving lower-income patients with none of the multi-channel cushion its counterparts had.

Private hospitals reliant on regular commercial supply, from Chennai to Bengaluru, reported running down reserve stock with no clear resupply date, forcing oncologists toward less effective, costlier substitute regimens for cancers where weekly cisplatin is central to treatment, such as cervical and head-and-neck chemoradiation.

The mechanism connecting the two ends is precise: DPCO ceiling prices are meant to stop manufacturers from overcharging in a functioning market, but they assume input costs stay roughly stable. When a global commodity shock hits an imported raw material, a fixed ceiling stops functioning as a fair price and starts functioning as a production disincentive.

NPPA's Paragraph 19 clause exists exactly for this failure mode - an emergency override that lets the regulator raise the ceiling fast enough to keep manufacturing viable, rather than watch the market solve the shortage through disappearance.

The 50 percent revision fixed the immediate viability problem. It did nothing for the structural one: India still imports the bulk of its platinum-based API, still has no strategic reserve of essential oncology drugs and still relies on a reactive price-revision mechanism rather than an early-warning system tied to global commodity movements.

The next raw material shock - platinum or otherwise - will reproduce the same gap between what a price cap assumes and what a global supply chain actually costs, unless procurement diversification and reserve stocks are built now, while the memory of empty vial counts at MNJ Institute is still fresh.